Latest News for: Wamd

Edit

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED BY THERAPEUTIC GOODS ADMINISTRATION, AUSTRALIA (Shanghai Henlius Biotech Inc)

Public Technologies 29 Jan 2021
APPLICATION FOR CLINICAL TRIAL FOR RECOMBINANT ANTI-VEGF HUMANIZED MONOCLONAL ANTIBODY OPHTHALMIC INJECTION HLX04-O FOR THE TREATMENT OF WET AGE-RELATED MACULAR DEGENERATION (wAMD) APPROVED BY THERAPEUTIC GOODS ADMINISTRATION, AUSTRALIA INTRODUCTION.
  • 1

Most Viewed

×